Evidence map›Paper›PMID 37821565›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2023

Endocrine causes of hypertension: literature review and practical approach.

Jean-Baptiste de Freminville, Laurence Amar, Michel Azizi, Julien Mallart-Riancho

Abstract readReview
PubMed Publisher
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jean-Baptiste de FreminvilleHypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015, Paris, France. jean.de-freminville@polytechnique.org.
Laurence AmarHypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015, Paris, France.
Michel AziziHypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015, Paris, France.
Julien Mallart-RianchoHypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015, Paris, France.
Université Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Européen Georges-Pompidou · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension (HTN) affects more than 30% of adults worldwide. It is the most frequent modifiable cardiovascular (CV) risk factor, and is responsible for more than 10 million death every year. Among patients with HTN, we usually distinguish secondary HTN, that is HTN due to an identified cause, and primary HTN, in which no underlying cause has been found. It is estimated that secondary hypertension represents between 5 and 15% of hypertensive patients [1]. Therefore, routine screening of patients for secondary HTN would be too costly and is not recommended. In addition to the presence of signs suggesting a specific secondary cause, screening is based on specific criteria. Identifying secondary HTN can be beneficial for patients in certain situations, because it may lead to specific treatments, and allow better control of blood pressure and sometimes even a cure. Besides, it is now known that secondary HTN are more associated with morbidity and mortality than primary HTN. The main causes of secondary HTN are endocrine and renovascular (mainly due to renal arteries abnormalities). The most frequent endocrine cause is primary aldosteronism, which diagnosis can lead to specific therapies. Pheochromocytoma and Cushing syndrome also are important causes, and can have serious complications. Other causes are less frequent and can be suspected on specific situations. In this article, we will describe the endocrine causes of HTN and discuss their treatments.

Indexed as

Adrenal Gland NeoplasmsCushing SyndromeHypertensionPheochromocytomaAdultBlood PressureHumansAldosteronismHypertensionPheochromocytomaSecondary hypertension.

Identifiers

PMID37821565
OpenAlexW4387517318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.